Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-11-30
DOI
10.2217/fon-2020-0655
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.
- (2020) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
- (2020) Christian Marth et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.
- (2020) Rebecca Sophie Kristeleit et al. JOURNAL OF CLINICAL ONCOLOGY
- ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC).
- (2020) Mansoor Raza Mirza et al. JOURNAL OF CLINICAL ONCOLOGY
- 1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
- (2020) J. Subramanian et al. ANNALS OF ONCOLOGY
- Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
- (2020) A. Oaknin et al. GYNECOLOGIC ONCOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
- (2019) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.
- (2019) Nashat Y. Gabrail et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
- (2019) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
- (2019) Yoland Catherine Antill et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
- (2019) Sean Matthew McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: a multicenter, open‐label phase 2 trial
- (2019) Kenji Tamura et al. CANCER SCIENCE
- Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer
- (2019) A. Oaknin et al. GYNECOLOGIC ONCOLOGY
- Immune-Related Adverse Events: A Case-Based Approach
- (2019) Caoilfhionn Connolly et al. Frontiers in Oncology
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
- (2019) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- 935PDPreliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
- (2018) A Oaknin et al. ANNALS OF ONCOLOGY
- A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
- (2018) Amit Maity et al. BRITISH JOURNAL OF CANCER
- Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
- (2017) Josee-Lyne Ethier et al. GYNECOLOGIC ONCOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
- (2017) Jennifer Sheng et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
- (2016) Piera Gargiulo et al. CANCER TREATMENT REVIEWS
- Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody
- (2016) H. Laken et al. EUROPEAN JOURNAL OF CANCER
- Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
- (2016) Valerie Lee et al. ONCOLOGIST
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
- (2015) S. Postel-Vinay et al. ANNALS OF ONCOLOGY
- PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy
- (2015) T.J. Herzog et al. GYNECOLOGIC ONCOLOGY
- The immune system in the normal endometrium and implications for endometrial cancer development
- (2015) A. Vanderstraeten et al. JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- Programmed death-1 pathway in cancer and autoimmunity
- (2014) Ariel Pedoeem et al. CLINICAL IMMUNOLOGY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
- (2013) Louise A. Brinton et al. GYNECOLOGIC ONCOLOGY
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies
- (2011) P. M. Bowers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- What is the Role of Chemotherapy in Endometrial Cancer?
- (2011) Thomas Hogberg Current Oncology Reports
- Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status
- (2009) F. Bellati et al. CURRENT CANCER DRUG TARGETS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started